Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

Stroke. 2011 Sep;42(9):2633-5. doi: 10.1161/STROKEAHA.111.618215. Epub 2011 Jul 7.

Abstract

Background and purpose: Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.

Methods: The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.

Results: Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019).

Conclusions: Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Brain Ischemia / blood*
  • Brain Ischemia / drug therapy*
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Humans
  • Infusions, Intravenous
  • Male
  • Matrix Metalloproteinase 9 / blood*
  • Matrix Metalloproteinase Inhibitors
  • Middle Aged
  • Minocycline / administration & dosage*
  • Stroke / blood*
  • Stroke / drug therapy*
  • Thrombolytic Therapy / methods
  • Tissue Plasminogen Activator / administration & dosage

Substances

  • Anti-Bacterial Agents
  • Fibrinolytic Agents
  • Matrix Metalloproteinase Inhibitors
  • Tissue Plasminogen Activator
  • Matrix Metalloproteinase 9
  • Minocycline